(IPN) Ipsen - Ratings and Ratios
Oncology, Rare Disease, Neuroscience, Biopharmaceuticals, Therapeutics
Dividends
| Dividend Yield | 1.34% |
| Yield on Cost 5y | 2.09% |
| Yield CAGR 5y | 8.78% |
| Payout Consistency | 97.4% |
| Payout Ratio | 26.1% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 24.2% |
| Value at Risk 5%th | 38.3% |
| Relative Tail Risk | -4.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.52 |
| Alpha | 9.34 |
| CAGR/Max DD | 0.43 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.557 |
| Beta | 0.018 |
| Beta Downside | 0.278 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.25% |
| Mean DD | 11.00% |
| Median DD | 11.53% |
Description: IPN Ipsen January 06, 2026
Ipsen S.A. is a French-based biopharmaceutical company that develops and markets medicines across three therapeutic pillars – oncology, rare disease, and neuroscience – serving patients worldwide. The firm trades on Euronext under the ticker IPN.
In oncology, Ipsen’s commercial portfolio includes Somatuline (for neuroendocrine tumors and acromegaly), Cabometyx (TKI for second-line neuroendocrine tumors), Onivyde (liposomal irinotecan for pancreatic cancer), Decapeptyl (advanced prostate cancer), and Tazverik (EZH2 inhibitor in Phase III for follicular lymphoma). Late-stage pipeline assets comprise Tovorafenib (Phase III first-line pediatric LGG; Phase II relapsed/refractory LGG) and early-stage candidates IPN01194/01195 (Phase I solid tumors).
In the rare-disease segment, Ipsen markets Bylvay (progressive familial intrahepatic cholestasis), Iqirvo (primary biliary cholangitis), NutropinAq (recombinant human growth hormone), and Increlex (IGF-1). Mid-stage programs include Fidrisertib (Phase II fibrodysplasia ossificans progressive) and Ritivixibat (Phase II primary sclerosing cholangitis).
Neuroscience offerings feature Dysport (botulinum toxin) – currently in Phase III for chronic and episodic migraine – and IPN10200, a pipeline candidate in Phase II for aesthetic and therapeutic indications.
Key financial and market drivers (2023 data):
• Revenue of approximately €2.9 billion, with oncology contributing roughly 50 % of sales.
• R&D expenditure of about €500 million, representing ~17 % of revenue, underscoring a strong pipeline investment.
• The global oncology drug market is projected to grow at a CAGR of ~8 % through 2030, providing tailwinds for Ipsen’s growth, while rare-disease therapies benefit from premium pricing and expanding patient-access programs in Europe and the U.S.
For a deeper quantitative view of Ipsen’s valuation dynamics, see the ValueRay analysis.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (1.13b TTM) > 0 and > 6% of Revenue (6% = 419.1m TTM) |
| FCFTA 0.23 (>2.0%) and ΔFCFTA 6.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 19.98% (prev 8.28%; Δ 11.70pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.27 (>3.0%) and CFO 1.88b > Net Income 1.13b (YES >=105%, WARN >=100%) |
| Net Debt (-483.2m) to EBITDA (2.50b) ratio: -0.19 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (83.5m) change vs 12m ago -0.01% (target <= -2.0% for YES) |
| Gross Margin 82.18% (prev 83.07%; Δ -0.90pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 106.2% (prev 51.90%; Δ 54.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 35.84 (EBITDA TTM 2.50b / Interest Expense TTM 50.0m) >= 6 (WARN >= 3) |
Altman Z'' 8.56
| (A) 0.20 = (Total Current Assets 2.81b - Total Current Liabilities 1.42b) / Total Assets 6.83b |
| (B) 0.61 = Retained Earnings (Balance) 4.19b / Total Assets 6.83b |
| (C) 0.27 = EBIT TTM 1.79b / Avg Total Assets 6.58b |
| (D) 3.23 = Book Value of Equity 8.39b / Total Liabilities 2.60b |
| Total Rating: 8.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.42
| 1. Piotroski 7.50pt |
| 2. FCF Yield 15.48% |
| 3. FCF Margin 22.54% |
| 4. Debt/Equity 0.23 |
| 5. Debt/Ebitda -0.19 |
| 6. ROIC - WACC (= 24.36)% |
| 7. RoE 27.74% |
| 8. Rev. Trend 75.06% |
| 9. EPS Trend -22.56% |
What is the price of IPN shares?
Over the past week, the price has changed by +4.02%, over one month by +11.99%, over three months by +18.29% and over the past year by +13.69%.
Is IPN a buy, sell or hold?
What are the forecasts/targets for the IPN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 129.3 | -3.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 149.4 | 11.1% |
IPN Fundamental Data Overview January 14, 2026
P/E Trailing = 24.0335
P/E Forward = 12.9199
P/S = 2.8338
P/B = 2.4819
P/EG = 0.7317
Revenue TTM = 6.99b EUR
EBIT TTM = 1.79b EUR
EBITDA TTM = 2.50b EUR
Long Term Debt = 745.6m EUR (from longTermDebt, last quarter)
Short Term Debt = 123.7m EUR (from shortTermDebt, last quarter)
Debt = 961.8m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -483.2m EUR (from netDebt column, last quarter)
Enterprise Value = 10.17b EUR (10.65b + Debt 961.8m - CCE 1.45b)
Interest Coverage Ratio = 35.84 (Ebit TTM 1.79b / Interest Expense TTM 50.0m)
EV/FCF = 6.46x (Enterprise Value 10.17b / FCF TTM 1.57b)
FCF Yield = 15.48% (FCF TTM 1.57b / Enterprise Value 10.17b)
FCF Margin = 22.54% (FCF TTM 1.57b / Revenue TTM 6.99b)
Net Margin = 16.16% (Net Income TTM 1.13b / Revenue TTM 6.99b)
Gross Margin = 82.18% ((Revenue TTM 6.99b - Cost of Revenue TTM 1.25b) / Revenue TTM)
Gross Margin QoQ = 82.14% (prev 83.43%)
Tobins Q-Ratio = 1.49 (Enterprise Value 10.17b / Total Assets 6.83b)
Interest Expense / Debt = 1.63% (Interest Expense 15.7m / Debt 961.8m)
Taxrate = 21.06% (89.5m / 425.0m)
NOPAT = 1.41b (EBIT 1.79b * (1 - 21.06%))
Current Ratio = 1.98 (Total Current Assets 2.81b / Total Current Liabilities 1.42b)
Debt / Equity = 0.23 (Debt 961.8m / totalStockholderEquity, last quarter 4.23b)
Debt / EBITDA = -0.19 (Net Debt -483.2m / EBITDA 2.50b)
Debt / FCF = -0.31 (Net Debt -483.2m / FCF TTM 1.57b)
Total Stockholder Equity = 4.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.17% (Net Income 1.13b / Total Assets 6.83b)
RoE = 27.74% (Net Income TTM 1.13b / Total Stockholder Equity 4.07b)
RoCE = 37.21% (EBIT 1.79b / Capital Employed (Equity 4.07b + L.T.Debt 745.6m))
RoIC = 29.95% (NOPAT 1.41b / Invested Capital 4.72b)
WACC = 5.59% (E(10.65b)/V(11.62b) * Re(5.98%) + D(961.8m)/V(11.62b) * Rd(1.63%) * (1-Tc(0.21)))
Discount Rate = 5.98% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.01%
[DCF Debug] Terminal Value 87.46% ; FCFF base≈1.37b ; Y1≈1.55b ; Y5≈2.10b
Fair Price DCF = 755.3 (EV 61.74b - Net Debt -483.2m = Equity 62.23b / Shares 82.4m; r=5.90% [WACC]; 5y FCF grow 15.13% → 2.90% )
EPS Correlation: -22.56 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 75.06 | Revenue CAGR: 55.75% | SUE: 1.09 | # QB: 1
EPS next Year (2026-12-31): EPS=11.31 | Chg30d=+0.045 | Revisions Net=+1 | Growth EPS=-3.5% | Growth Revenue=+4.2%